DK174237B1 - DNA-sekvenser, der koder for N2- eller N3-trunkerede former af den lange form og den korte form af CSF-1 og anvendelse heraf i vektorer, ekspressionssystemer, rekombinante værtsceller, samt en fremgangsmåde til fremstilling...... - Google Patents

DNA-sekvenser, der koder for N2- eller N3-trunkerede former af den lange form og den korte form af CSF-1 og anvendelse heraf i vektorer, ekspressionssystemer, rekombinante værtsceller, samt en fremgangsmåde til fremstilling...... Download PDF

Info

Publication number: DK174237B1
Authority: DK; Denmark
Prior art keywords: csf; lcsf; scsf; cells; sequence
Prior art date: 1986-10-24

Application number

DK198803501A

Other languages

Danish (da)

English (en)

Other versions

DK350188D0 (da

DK350188A (da

Inventor

Kirston Edward Koths

Robert Forgan Halenbeck

Ernest Seigo Kawasaki

Martha Ballie Ladner

Mazie Yee Coyne

George Arthur Martin

Janelle Nobel Van Arsdell

Original Assignee

Chiron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-10-24

Filing date

1988-06-24

Publication date

2002-10-07

1988-06-24 Application filed by Chiron Corp filed Critical Chiron Corp

1988-06-24 Publication of DK350188D0 publication Critical patent/DK350188D0/da

1988-08-19 Publication of DK350188A publication Critical patent/DK350188A/da

2002-10-07 Application granted granted Critical

2002-10-07 Publication of DK174237B1 publication Critical patent/DK174237B1/da

Links

102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 title claims abstract description 192
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 title claims abstract description 192
230000014509 gene expression Effects 0.000 title claims abstract description 65
108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 28
239000013598 vector Substances 0.000 title claims description 75
238000000034 method Methods 0.000 title claims description 44
238000002360 preparation method Methods 0.000 title description 17
108090000623 proteins and genes Proteins 0.000 claims abstract description 152
102000004169 proteins and genes Human genes 0.000 claims abstract description 115
210000004027 cell Anatomy 0.000 claims description 116
108020004414 DNA Proteins 0.000 claims description 56
150000001413 amino acids Chemical class 0.000 claims description 51
101000916628 Homo sapiens Macrophage colony-stimulating factor 1 Proteins 0.000 claims description 30
102000053925 human CSF1 Human genes 0.000 claims description 29
238000004519 manufacturing process Methods 0.000 claims description 26
210000002540 macrophage Anatomy 0.000 claims description 24
238000003556 assay Methods 0.000 claims description 23
210000004899 c-terminal region Anatomy 0.000 claims description 23
125000003275 alpha amino acid group Chemical group 0.000 claims description 22
238000012217 deletion Methods 0.000 claims description 18
230000037430 deletion Effects 0.000 claims description 18
239000000203 mixture Substances 0.000 claims description 18
230000015572 biosynthetic process Effects 0.000 claims description 17
239000000539 dimer Substances 0.000 claims description 15
230000004048 modification Effects 0.000 claims description 15
238000012986 modification Methods 0.000 claims description 15
238000000338 in vitro Methods 0.000 claims description 9
108090000765 processed proteins & peptides Proteins 0.000 claims description 6
230000008569 process Effects 0.000 claims description 5
102000004196 processed proteins & peptides Human genes 0.000 claims description 4
229920001184 polypeptide Polymers 0.000 claims description 3
101150111020 GLUL gene Proteins 0.000 claims 1
240000008881 Oenanthe javanica Species 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
238000010367 cloning Methods 0.000 abstract description 6
210000000987 immune system Anatomy 0.000 abstract description 5
102000007644 Colony-Stimulating Factors Human genes 0.000 abstract description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 abstract description 2
241001529936 Murinae Species 0.000 abstract description 2
238000010188 recombinant method Methods 0.000 abstract description 2
230000001105 regulatory effect Effects 0.000 abstract 1
235000018102 proteins Nutrition 0.000 description 111
230000000694 effects Effects 0.000 description 62
235000001014 amino acid Nutrition 0.000 description 55
229940024606 amino acid Drugs 0.000 description 54
239000012634 fragment Substances 0.000 description 43
239000000523 sample Substances 0.000 description 43
108020004705 Codon Proteins 0.000 description 39
239000002299 complementary DNA Substances 0.000 description 35
241000588724 Escherichia coli Species 0.000 description 34
108091026890 Coding region Proteins 0.000 description 33
239000013612 plasmid Substances 0.000 description 29
241000699666 Mus <mouse, genus> Species 0.000 description 27
210000001185 bone marrow Anatomy 0.000 description 19
239000006228 supernatant Substances 0.000 description 18
238000000746 purification Methods 0.000 description 17
238000011282 treatment Methods 0.000 description 17
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
239000002609 medium Substances 0.000 description 16
208000015181 infectious disease Diseases 0.000 description 15
238000012545 processing Methods 0.000 description 15
239000013615 primer Substances 0.000 description 14
239000000047 product Substances 0.000 description 14
108020004999 messenger RNA Proteins 0.000 description 13
238000004458 analytical method Methods 0.000 description 12
239000013604 expression vector Substances 0.000 description 12
230000013595 glycosylation Effects 0.000 description 12
238000006206 glycosylation reaction Methods 0.000 description 12
238000009396 hybridization Methods 0.000 description 12
229930182817 methionine Natural products 0.000 description 12
239000000178 monomer Substances 0.000 description 12
239000000243 solution Substances 0.000 description 12
125000000539 amino acid group Chemical group 0.000 description 11
210000002700 urine Anatomy 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
240000004808 Saccharomyces cerevisiae Species 0.000 description 10
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 10
241000894007 species Species 0.000 description 10
238000011144 upstream manufacturing Methods 0.000 description 10
241000894006 Bacteria Species 0.000 description 9
206010028980 Neoplasm Diseases 0.000 description 9
108091034117 Oligonucleotide Proteins 0.000 description 9
230000001580 bacterial effect Effects 0.000 description 9
230000000295 complement effect Effects 0.000 description 9
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 9
238000011534 incubation Methods 0.000 description 9
210000004962 mammalian cell Anatomy 0.000 description 9
239000002773 nucleotide Substances 0.000 description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
230000000638 stimulation Effects 0.000 description 9
241000238631 Hexapoda Species 0.000 description 8
108091000080 Phosphotransferase Proteins 0.000 description 8
238000010276 construction Methods 0.000 description 8
238000003780 insertion Methods 0.000 description 8
230000037431 insertion Effects 0.000 description 8
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 8
210000001616 monocyte Anatomy 0.000 description 8
125000003729 nucleotide group Chemical group 0.000 description 8
102000020233 phosphotransferase Human genes 0.000 description 8
230000010076 replication Effects 0.000 description 8
238000004007 reversed phase HPLC Methods 0.000 description 8
230000009466 transformation Effects 0.000 description 8
102000004594 DNA Polymerase I Human genes 0.000 description 7
108010017826 DNA Polymerase I Proteins 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
108010074338 Lymphokines Proteins 0.000 description 7
102000008072 Lymphokines Human genes 0.000 description 7
210000002798 bone marrow cell Anatomy 0.000 description 7
238000001516 cell proliferation assay Methods 0.000 description 7
230000006870 function Effects 0.000 description 7
230000035772 mutation Effects 0.000 description 7
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical class [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 7
238000003127 radioimmunoassay Methods 0.000 description 7
108091008146 restriction endonucleases Proteins 0.000 description 7
238000010561 standard procedure Methods 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
108010076504 Protein Sorting Signals Proteins 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
239000000872 buffer Substances 0.000 description 6
230000003196 chaotropic effect Effects 0.000 description 6
235000018417 cysteine Nutrition 0.000 description 6
239000000499 gel Substances 0.000 description 6
230000012010 growth Effects 0.000 description 6
239000012528 membrane Substances 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
230000028327 secretion Effects 0.000 description 6
238000012163 sequencing technique Methods 0.000 description 6
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
102100031939 Erythropoietin Human genes 0.000 description 5
101000916629 Mus musculus Macrophage colony-stimulating factor 1 Proteins 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
241000183024 Populus tremula Species 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
241000700605 Viruses Species 0.000 description 5
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
244000309464 bull Species 0.000 description 5
239000003638 chemical reducing agent Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
230000029087 digestion Effects 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
230000001323 posttranslational effect Effects 0.000 description 5
238000005215 recombination Methods 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 4
102000014150 Interferons Human genes 0.000 description 4
108010050904 Interferons Proteins 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
JJWSNOOGIUMOEE-UHFFFAOYSA-N Monomethylmercury Chemical compound [Hg]C JJWSNOOGIUMOEE-UHFFFAOYSA-N 0.000 description 4
108091081024 Start codon Proteins 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
210000001175 cerebrospinal fluid Anatomy 0.000 description 4
238000006471 dimerization reaction Methods 0.000 description 4
210000003714 granulocyte Anatomy 0.000 description 4
150000007523 nucleic acids Chemical class 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
230000008488 polyadenylation Effects 0.000 description 4
230000006798 recombination Effects 0.000 description 4
239000000758 substrate Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
230000010474 transient expression Effects 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
241001646716 Escherichia coli K-12 Species 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 3
102000003839 Human Proteins Human genes 0.000 description 3
108090000144 Human Proteins Proteins 0.000 description 3
102000000589 Interleukin-1 Human genes 0.000 description 3
108010002352 Interleukin-1 Proteins 0.000 description 3
108010002386 Interleukin-3 Proteins 0.000 description 3
102000000646 Interleukin-3 Human genes 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
238000000636 Northern blotting Methods 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
238000007792 addition Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
210000000601 blood cell Anatomy 0.000 description 3
239000011575 calcium Substances 0.000 description 3
230000008859 change Effects 0.000 description 3
230000000973 chemotherapeutic effect Effects 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
230000002281 colonystimulating effect Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
230000008629 immune suppression Effects 0.000 description 3
239000012535 impurity Substances 0.000 description 3
230000006698 induction Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
230000003448 neutrophilic effect Effects 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
238000011084 recovery Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
108091028026 C-DNA Proteins 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
102000012410 DNA Ligases Human genes 0.000 description 2
108010061982 DNA Ligases Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
108700007698 Genetic Terminator Regions Proteins 0.000 description 2
QJCKNLPMTPXXEM-AUTRQRHGSA-N Glu-Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O QJCKNLPMTPXXEM-AUTRQRHGSA-N 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
108010053070 Glutathione Disulfide Proteins 0.000 description 2
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
101100168719 Mus musculus Csf1 gene Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
102100040247 Tumor necrosis factor Human genes 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000004075 alteration Effects 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
238000004873 anchoring Methods 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000001212 derivatisation Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
150000002019 disulfides Chemical class 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000005227 gel permeation chromatography Methods 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
125000000291 glutamic acid group Chemical class N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
230000002414 glycolytic effect Effects 0.000 description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
238000002372 labelling Methods 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
238000005457 optimization Methods 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
101150009573 phoA gene Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
230000003169 placental effect Effects 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000012064 sodium phosphate buffer Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000013589 supplement Substances 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
-1 thiol compound Chemical class 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
238000001890 transfection Methods 0.000 description 2
238000000844 transformation Methods 0.000 description 2
230000014616 translation Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
102000013563 Acid Phosphatase Human genes 0.000 description 1
108010051457 Acid Phosphatase Proteins 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
201000010000 Agranulocytosis Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
101100291398 Arabidopsis thaliana MLO6 gene Proteins 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000304886 Bacilli Species 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
230000004543 DNA replication Effects 0.000 description 1
230000007018 DNA scission Effects 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
241001524679 Escherichia virus M13 Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
102000030595 Glucokinase Human genes 0.000 description 1
108010021582 Glucokinase Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
206010018687 Granulocytopenia Diseases 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
102000005548 Hexokinase Human genes 0.000 description 1
108700040460 Hexokinases Proteins 0.000 description 1
IMCHNUANCIGUKS-SRVKXCTJSA-N His-Glu-Arg Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IMCHNUANCIGUKS-SRVKXCTJSA-N 0.000 description 1
101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
241000282620 Hylobates sp. Species 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
102000004388 Interleukin-4 Human genes 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
101150007280 LEU2 gene Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
101000746372 Mus musculus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
101001033276 Mus musculus Interleukin-3 Proteins 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
108010087702 Penicillinase Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
241001135910 Phage M13mp18 Species 0.000 description 1
108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
102000013009 Pyruvate Kinase Human genes 0.000 description 1
108020005115 Pyruvate Kinase Proteins 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
108020005091 Replication Origin Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
LAFKUZYWNCHOHT-WHFBIAKZSA-N Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O LAFKUZYWNCHOHT-WHFBIAKZSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000008043 acidic salts Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000009118 appropriate response Effects 0.000 description 1
239000012223 aqueous fraction Substances 0.000 description 1
238000003491 array Methods 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000008827 biological function Effects 0.000 description 1
229910021538 borax Inorganic materials 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
239000004020 conductor Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000022811 deglycosylation Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
238000000151 deposition Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
125000002228 disulfide group Chemical group 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000009585 enzyme analysis Methods 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
210000000222 eosinocyte Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
102000055276 human IL3 Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000001320 lysogenic effect Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000013011 mating Effects 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
108010058731 nopaline synthase Proteins 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
229950009506 penicillinase Drugs 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
238000007692 polyacrylamide-agarose gel electrophoresis Methods 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000003134 recirculating effect Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
235000010339 sodium tetraborate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000011191 terminal modification Methods 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000011426 transformation method Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
150000005691 triesters Chemical class 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
230000005909 tumor killing Effects 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
238000012795 verification Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyrane Compounds (AREA)
Liquid Crystal Substances (AREA)
Luminescent Compositions (AREA)

DK198803501A 1986-10-24 1988-06-24 DNA-sekvenser, der koder for N2- eller N3-trunkerede former af den lange form og den korte form af CSF-1 og anvendelse heraf i vektorer, ekspressionssystemer, rekombinante værtsceller, samt en fremgangsmåde til fremstilling...... DK174237B1 (da)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US92306786A	1986-10-24	1986-10-24
US92306786		1986-10-24
US3965787A	1987-04-16	1987-04-16
US3965487A	1987-04-16	1987-04-16
US3965487		1987-04-16
US3965787		1987-04-16
PCT/US1987/002679 WO1988003173A2 (en)	1986-10-24	1987-10-16	New forms of colony stimulating factor-1
US8702679		1987-10-16

Publications (3)

Publication Number	Publication Date
DK350188D0 DK350188D0 (da)	1988-06-24
DK350188A DK350188A (da)	1988-08-19
DK174237B1 true DK174237B1 (da)	2002-10-07

Family

ID=27365583

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK198803501A DK174237B1 (da)	1986-10-24	1988-06-24	DNA-sekvenser, der koder for N2- eller N3-trunkerede former af den lange form og den korte form af CSF-1 og anvendelse heraf i vektorer, ekspressionssystemer, rekombinante værtsceller, samt en fremgangsmåde til fremstilling......

Country Status (12)

Country	Link
EP (1)	EP0272779B1 (de)
JP (1)	JP2644794B2 (de)
AT (1)	ATE105869T1 (de)
AU (2)	AU8007087A (de)
CA (1)	CA1339032C (de)
DE (1)	DE3789859T2 (de)
DK (1)	DK174237B1 (de)
ES (1)	ES2052580T3 (de)
FI (1)	FI102190B (de)
HU (1)	HU215241B (de)
NO (1)	NO301775B1 (de)
WO (1)	WO1988003173A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5422105A (en) *	1985-02-05	1995-06-06	Cetus Oncology Corporation	Use of recombinant colony stimulating factor 1
US5104650A (en) *	1985-02-05	1992-04-14	Cetus Corporation	Uses of recombinant colony stimulating factor-1
US5837229A (en) *	1985-02-05	1998-11-17	Chiron Corporation	Uses of recombinant colony stimulating factor-1
US5573930A (en) *	1985-02-05	1996-11-12	Cetus Oncology Corporation	DNA encoding various forms of colony stimulating factor-1
US6156300A (en) *	1985-02-05	2000-12-05	Chiron Corporation	Point mutants of N∇2 CSF-1 and carboxy truncated fragments thereof
US6103224A (en) *	1985-02-05	2000-08-15	Chiron Corporation	N∇2 CSF-1 (short form) and carboxy truncated fragments thereof
US5556620A (en) *	1985-02-05	1996-09-17	Cetus Oncology Corporation	Use of recombinant colony stimulating factor-1 to enhance wound healing
AU595864B2 (en) *	1986-03-14	1990-04-12	Otsuka Pharmaceutical Co., Ltd.	Il-1 alpha derivatives and drugs
WO1987006954A1 (en) *	1986-05-06	1987-11-19	Genetics Institute, Inc.	Production of m-csf
US5650297A (en) *	1986-09-17	1997-07-22	Otsuka Pharmaceutical Co., Ltd.	DNA encoding human colony-stimulating factors
JP2583829B2 (ja) *	1986-09-17	1997-02-19	大塚製薬株式会社	ヒトｍ−ｃｓｆ
JP2583770B2 (ja) *	1986-09-17	1997-02-19	大塚製薬株式会社	遺伝子
DE3777623D1 (de) *	1986-12-07	1992-04-23	Morinaga Milk Industry Co Ltd	Kolonie-stimulierender faktor und verfahren zu seiner herstellung.
US4929700A (en) *	1987-04-16	1990-05-29	Cetus Corporation	Production of purified, biologically active, bacterially produced recombinant human CSF-1
CA1339757C (en) *	1987-04-16	1998-03-17	Robert F. Halenbeck	Production of purified biologically active, bacterially produced recombinant human csf-1
CA1317244C (en) *	1987-07-24	1993-05-04	Ernest Seigo Kawasaki	Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system
DK54589A (da) *	1988-02-08	1989-08-09	Otsuka Pharma Co Ltd	Humane kolonistmulerende faktorer
JPH0610137B2 (ja) *	1988-02-29	1994-02-09	新技術事業団	ヒト単球−マクロファージコロニー刺激因子を有効成分とする造血器疾患治療剤
US5171675A (en) *	1988-07-28	1992-12-15	Cerretti Douglas P	Macrophage colony stimulating factor-γ
WO1990012877A1 (en) *	1989-04-19	1990-11-01	Cetus Corporation	Multifunctional m-csf proteins and genes encoding therefor
DE69026440T2 (de) *	1989-07-27	1996-10-17	Denki Kagaku Kogyo Kk	Für M-CSF kodierendes Gen und dazu gehörende rekombinante Systeme
KR920701253A (ko) *	1989-11-07	1992-08-11	오오쓰까 아끼히꼬	M-csf 유도체, 그 유도체의 발현 벡터, 그 벡터를 갖는 형질 전환체 및 이들의 제조방법
US5714140A (en) *	1989-12-13	1998-02-03	Otsuka Pharmaceutical Co., Ltd.	Method for inhibiting the production of bioactive IL-1 by administering M-CSF
DE4014750A1 (de) *	1990-05-08	1991-11-14	Boehringer Mannheim Gmbh	Muteine des granulozyten-stimulierenden faktors (g-csf)
AU639091B2 (en) *	1991-04-24	1993-07-15	Otsuka Pharmaceutical Co., Ltd.	M-csf derivatives, expression vectors for said derivatives, transformants carrying said vectors and production of these
CA2137793C (en)	1992-06-09	2003-04-22	Jayvardhan Pandit	Crystallization of m-csf
AU6125294A (en) *	1993-01-13	1994-08-15	Genetics Institute Inc.	Process for producing m-csf 223
GB2355791B (en)	1999-10-28	2004-10-20	Molecular Light Tech Res Ltd	Detection of mRNA expression using chemiluminescent labelled probes
KR100371264B1 (ko) *	2000-01-25	2003-02-05	양문식	무라인 그래뉼로사이트-매크로파지 콜로니 자극 인자를포함하는 재조합 벡터와 그것을 발현하는 재조합아스퍼질러스 나이거
DK2485583T3 (en)	2009-10-06	2016-10-03	Regeneron Pharma	GENETICALLY MODIFIED MICE AND inoculation
PT3375284T (pt) *	2011-02-15	2023-06-28	Univ Yale	Ratinhos humanizados para m-csf e utilizações dos mesmos
IL282472B2 (en)	2012-09-07	2024-04-01	Regeneron Pharma	Genetically modified non-human animals and methods of their use
CN114766432B (zh)	2012-11-05	2024-08-02	再生元制药公司	经遗传修饰的非人动物及其使用方法
ES2964597T3 (es)	2014-05-19	2024-04-08	Regeneron Pharma	Ratones modificados genéticamente que expresan EPO humana
DK3282835T3 (da)	2015-04-13	2023-06-26	Regeneron Pharma	Humaniserede SIRP?-IL-15-knockin-mus og fremgangsmåder til anvendelse deraf

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0209601B1 (de) *	1985-02-05	1993-12-15	Cetus Oncology Corporation	Rekombinanter koloniestimulierender faktor-1
JP2583770B2 (ja) *	1986-09-17	1997-02-19	大塚製薬株式会社	遺伝子

1987
- 1987-10-16 HU HU876048A patent/HU215241B/hu not_active IP Right Cessation
- 1987-10-16 WO PCT/US1987/002679 patent/WO1988003173A2/en active IP Right Grant
- 1987-10-16 JP JP62507123A patent/JP2644794B2/ja not_active Expired - Lifetime
- 1987-10-23 ES ES87309409T patent/ES2052580T3/es not_active Expired - Lifetime
- 1987-10-23 CA CA000550127A patent/CA1339032C/en not_active Expired - Fee Related
- 1987-10-23 EP EP87309409A patent/EP0272779B1/de not_active Expired - Lifetime
- 1987-10-23 AU AU80070/87A patent/AU8007087A/en not_active Abandoned
- 1987-10-23 AT AT87309409T patent/ATE105869T1/de not_active IP Right Cessation
- 1987-10-23 DE DE3789859T patent/DE3789859T2/de not_active Expired - Fee Related
1988
- 1988-06-22 NO NO882772A patent/NO301775B1/no not_active IP Right Cessation
- 1988-06-23 FI FI883056A patent/FI102190B/fi not_active IP Right Cessation
- 1988-06-24 DK DK198803501A patent/DK174237B1/da not_active IP Right Cessation
1991
- 1991-07-30 AU AU81494/91A patent/AU646277B2/en not_active Ceased

Also Published As

Publication number	Publication date
AU8007087A (en)	1988-04-28
FI883056L (fi)	1988-06-23
DK350188D0 (da)	1988-06-24
NO301775B1 (no)	1997-12-08
DK350188A (da)	1988-08-19
CA1339032C (en)	1997-04-01
WO1988003173A2 (en)	1988-05-05
HU215241B (hu)	1998-11-30
JPH01501283A (ja)	1989-05-11
JP2644794B2 (ja)	1997-08-25
HUT47635A (en)	1989-03-28
FI102190B1 (fi)	1998-10-30
NO882772D0 (no)	1988-06-22
EP0272779A2 (de)	1988-06-29
NO882772L (no)	1988-08-22
WO1988003173A3 (en)	1988-07-28
AU646277B2 (en)	1994-02-17
AU8149491A (en)	1991-10-31
ATE105869T1 (de)	1994-06-15
EP0272779B1 (de)	1994-05-18
ES2052580T3 (es)	1994-07-16
DE3789859T2 (de)	1994-09-15
FI883056A0 (fi)	1988-06-23
EP0272779A3 (en)	1988-08-03
DE3789859D1 (de)	1994-06-23
FI102190B (fi)	1998-10-30

Publication	Publication Date	Title
DK174237B1 (da)	2002-10-07	DNA-sekvenser, der koder for N2- eller N3-trunkerede former af den lange form og den korte form af CSF-1 og anvendelse heraf i vektorer, ekspressionssystemer, rekombinante værtsceller, samt en fremgangsmåde til fremstilling......
FI100972B (fi)	1998-03-31	Pesäkkeitä stimuloivaa tekijä-1:tä (CSF-1) koodaava DNA-sekvenssi ja m enetelmä CSF-1-proteiinin valmistamiseksi
US4847201A (en)	1989-07-11	DNA encoding for CSF-1 and accompanying recombinant systems
US4677064A (en)	1987-06-30	Human tumor necrosis factor
US4677063A (en)	1987-06-30	Human tumor necrosis factor
FI99015C (fi)	1997-09-25	Menetelmä biologisesti aktiivisen kasvaimen nekroositekijä-proteiinin muteiinin valmistamiseksi
WO1988003173A9 (en)	1998-10-08	New forms of colony stimulating factor-1
DK175412B1 (da)	2004-09-27	Fremgangsmåde til fremstilling af TGF-beta, DNA og mRNA, som koder for TGF-beta, samt replicerbare vektorer omfattende DNA'en og værtsceller indeholdende vektorerne
EP0256843A1 (de)	1988-02-24	Expression von G-CSF, Muteine davon und deren Verwendung
AU589919B2 (en)	1989-10-26	Human tumor necrosis factor
US5573930A (en)	1996-11-12	DNA encoding various forms of colony stimulating factor-1
US5104650A (en)	1992-04-14	Uses of recombinant colony stimulating factor-1
US6103224A (en)	2000-08-15	N∇2 CSF-1 (short form) and carboxy truncated fragments thereof
US6156300A (en)	2000-12-05	Point mutants of N∇2 CSF-1 and carboxy truncated fragments thereof
CA1339873C (en)	1998-05-19	Recombinant colony stimulating factor-1
KR970004941B1 (ko)	1997-04-10	신규 영장류 조혈 성장 인자족(family) 발현용 벡터 및 형질전환체

Legal Events

Date	Code	Title	Description
2002-10-07	B1	Patent granted (law 1993)
2004-06-07	PBP	Patent lapsed	Country of ref document: DK